Breaking Finance News

Needham disclosed Alnylam Pharma (NASDAQ:ALNY), bumping down its price target to $137.00 earlier today

Indicating a possible upside of 0.95%, Needham lowered the target price of Alnylam Pharma (NASDAQ:ALNY) to $137.00

On Thursday September 29, 2016, Janney Capital released a statement about Alnylam Pharma (NASDAQ:ALNY) raised the target price from $0.00 to $74.00. At the time, this suggested a downside of -0.03%.

Boasting a price of $70.30, Alnylam Pharma (NASDAQ:ALNY) traded 2.52% higher on the day. The last stock close price is up 5.78% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $72.86 and a 200-day moving average of $66.46. Volume of trade was up over the average, with 1,965,395 shares of ALNY changing hands over the typical 643,269

Performance Chart

Alnylam Pharma (NASDAQ:ALNY)

Alnylam Pharma has 52 week low of $49.96 and a 52 week high of $110.75 and has a market capitalization of $0.

In addition to Needham reporting its stock price target, a total of 11 brokers have issued a research note on Alnylam Pharma. The 12-month price target is $117.09 with three brokerages rating the company a strong buy, eight brokerages rating the company a buy, two brokerages rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Alnylam Pharma (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.